# Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

> **NCT00230958** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 900 (—)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Viramidine
- **DRUG:** Ribavirin
- **DRUG:** pegylated interferon alfa-2b

## Key facts

- **NCT ID:** NCT00230958
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 900 (—)
- **Last updated:** 2012-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230958, "Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00230958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*